skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site


Efficacy of dasatinib for the treatment of intractable chronic myeloid leukemia


(5429) Total Article Views

Authors: Lisa M Lima, Martha Arellano, Stacie Holloway, et al

Published Date September 2010 Volume 2010:1 Pages 221 - 225

Lisa M Lima, Martha Arellano, Stacie Holloway, Marian Shepard, Stephanie McMillan, Hanna Jean Khoury
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA

Abstract: Dasatinib (DAS) is a well tolerated oral dual SRC inhibitor with remarkable activity against all phases of imatinib-resistant chronic myeloid leukemia (CML). This paper focuses on the activity of DAS in intractable CML, and reviews outcomes of patients enrolled on DAS clinical trials. Safety and tolerability as well as practical tips for management of side-effects, and drug interactions are included.

Keywords: dasatinib, resistant CML, outcomes

Post to:
Cannotea Citeulike Facebook LinkedIn Twitter


Other articles by Dr Jean Khoury

Readers of this article also read: